AllianceBernstein (AB) –
-
AB to Report First Quarter 2024 Results on April 25, 2024
-
Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Apr 09
-
AB Announces March 31, 2024 Assets Under Management
-
AllianceBernstein (AB) PT Raised to $40 at TD Cowen
-
Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Apr 01
-
SOCIETE GENERALE AND ALLIANCEBERNSTEIN ANNOUNCE THE OFFICIAL LAUNCH OF BERNSTEIN, A NEW LEADER IN CASH EQUITIES & RESEARCH
-
AllianceBernstein (AB) PT Raised to $38 at Evercore ISI
-
Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Mar 11
-
AB Announces February 29, 2024 Assets Under Management
-
Form 3 ALLIANCEBERNSTEIN HOLDIN For: Mar 01 Filed by: MARKS JACQUELINE
-
AB Science provides a summary of the live webcast held on March 4, 2024 giving an update on AB Science development
-
AB Science announces that two financial analysis firms, DNA Finance and In Extenso Finance, have initiated coverage of the Company
-
Form 4 ALLIANCEBERNSTEIN HOLDIN For: Feb 28 Filed by: Siemers William R
-
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
-
AB Science will host a live webcast on Monday March 4, 2024, from 6.30pm to 7.30pm CET
-
AB Science announces that Health Canada has issued a Notice of Non-Compliance-Withdrawal (NON/w) for masitinib in ALS
-
Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Feb 12
-
AB Announces January 31, 2024 Assets Under Management
-
Form 10-K ALLIANCEBERNSTEIN HOLDIN For: Dec 31
-
AllianceBernstein (AB) PT Raised to $37 at Evercore ISI
-
Seth Bernstein, President and CEO, to Participate in the Bank of America 2024 Financial Services Conference on February 21st, 2024
-
AllianceBernstein (AB) Tops Q4 EPS by 14c
-
Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Feb 06
-
ALLIANCEBERNSTEIN HOLDING L.P. ANNOUNCES FOURTH QUARTER RESULTS
-
Bernstein Private Wealth Management Announces Expansion of Ultrahigh-Net-Worth Platform
-
Ryanair narrows full-year guidance following travel agent sales stoppage
-
AB Science announces an update in the marketing authorization application of masitinib in amyotrophic lateral sclerosis at the European Medicines Agency
-
Form 5 ALLIANCEBERNSTEIN HOLDIN For: Dec 31 Filed by: MANLEY MARK R
-
Form 3 ALLIANCEBERNSTEIN HOLDIN For: Jan 16 Filed by: Spencer Catherine R.
-
Form 4/A ALLIANCEBERNSTEIN HOLDIN For: Dec 01 Filed by: Simeone Thomas
-
AB to Report Fourth Quarter 2023 Results on February 6, 2024
-
Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Jan 17
-
AB Science receives notice of allowance for European patent covering masitinib until 2036 in the treatment of mastocytosis
-
Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Jan 10
-
AB Announces December 31, 2023 Assets Under Management
-
AllianceBernstein (AB) PT Raised to $33 at Jefferies
-
Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Jan 08
-
Jackie Marks Joins AllianceBernstein as Chief Financial Officer
-
Form 3 ALLIANCEBERNSTEIN HOLDIN For: Jan 01 Filed by: Hogbin Christopher
-
Bitcoin slips, extending recent decline from 2024 high
-
TD Cowen Starts AllianceBernstein (AB) at Outperform
-
Form 4 ALLIANCEBERNSTEIN HOLDIN For: Dec 12 Filed by: Simeone Thomas
-
Form 4 ALLIANCEBERNSTEIN HOLDIN For: Dec 12 Filed by: Erzan Onur
-
Form 4 ALLIANCEBERNSTEIN HOLDIN For: Dec 12 Filed by: Sprules Karl
-
Form 4 ALLIANCEBERNSTEIN HOLDIN For: Dec 12 Filed by: MANLEY MARK R
-
Form 4 ALLIANCEBERNSTEIN HOLDIN For: Dec 12 Filed by: Siemers William R
-
Form 4 ALLIANCEBERNSTEIN HOLDIN For: Dec 12 Filed by: BERNSTEIN SETH P
-
Form 4 ALLIANCEBERNSTEIN HOLDIN For: Dec 11 Filed by: MANLEY MARK R
-
AllianceBernstein Launches Five New Active ETFs
-
AllianceBernstein Announces Global Head of Investments
Back to AB Stock Lookup